Echo Therapeutics Announces Pricing of Public Offering of Common Stock

    Echo Therapeutics Announces Pricing of Public Offering of Common Stock

PR Newswire

PHILADELPHIA, Jan. 31, 2013

PHILADELPHIA, Jan. 31, 2013 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq:
ECTE), a company developing its needle-free Symphony^® tCGM System as a
non-invasive, wireless, transdermal continuous glucose monitoring system,
today announced the pricing of a previously announced underwritten public
offering of 13,333,333 shares of its common stock, offered at a price to the
public of $0.75 per share. The gross proceeds to Echo from this offering are
expected to be approximately $10.0 million, before deducting the underwriting
discount and other estimated offering expenses payable by Echo. Echo
Therapeutics has granted the underwriters a 45-day option to purchase up to an
aggregate of 2,000,000 additional shares of its common stock to cover
over-allotments, if any. The offering is expected to close on or about
February 6, 2013, subject to customary closing conditions.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

Aegis Capital Corp. is acting as the sole book-running manager for the
offering.

The offering is being made pursuant to a shelf registration statement that
Echo previously filed with the Securities and Exchange Commission (the "SEC")
and which is effective. A preliminary prospectus supplement and accompanying
base prospectus relating to the offering were filed with the SEC, and a final
prospectus supplement and accompanying base prospectus will be filed with the
SEC. Electronic copies of the preliminary prospectus supplement and, when
available, electronic copies of the final prospectus supplement, as well as
accompanying base prospectus, may be obtained by contacting Aegis Capital
Corp., Prospectus Department, 810 Seventh Avenue, 18^th Floor, New York, NY,
10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com. Electronic
copies of the final prospectus supplement and accompanying base prospectus
will also be available on the SEC's website located at www.sec.gov.

This press release does not constitute an offer to sell, or the solicitation
of an offer to buy, these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale is not permitted.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive,
wireless, transdermal continuous glucose monitoring system. Our target is
patients who could benefit from glucose monitoring in the hospital setting,
including critical care. Significant opportunity also exists for patients
with diabetes to use Symphony in the outpatient setting. Echo is also
developing its needle-free skin preparation component of Symphony, the
Prelude^® SkinPrep System, as a platform technology to enhance drug delivery
of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements, including statements regarding Echo's
proposed public offering. These statements are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
risks related to general market conditions and the other risks and
uncertainties identified and described in more detail in Echo's filings with
the Securities and Exchange Commission. Echo undertakes no obligation to
publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104
colimpio@echotx.com

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx



SOURCE Echo Therapeutics, Inc.

Website: http://www.echotx.com